TY - JOUR
T1 - Multidisciplinary management and outcomes of abdominal vascular graft and endograft infections
T2 - a retrospective cohort study
AU - Christensen, Anna Juul
AU - Bjerrum, Stephanie
AU - Sörelius, Karl
AU - Mathiesen, Inger Hee Mabuza
AU - Vogt, Katja
AU - Moser, Claus
AU - Helweg-Larsen, Jannik
AU - Sandholt, Benjamin Vikjaer
AU - Faurholt-Jepsen, Daniel
AU - Kraef, Christian
N1 - Publisher Copyright:
© The Author(s) 2026.
PY - 2026
Y1 - 2026
N2 - Purpose: To describe the multidisciplinary management and outcomes of patients with vascular graft and endograft infections of the abdominal aorta (aVGEI) in Eastern Denmark. Methods: Retrospective cohort study of aVGEI patients between 1st July 2022 and 30th June 2025. Diagnosis and management were based on a multidisciplinary team (MDT) conference. The primary outcome was 90-day mortality. Secondary outcomes included one-year mortality, cure, remission, treatment failure, and re-hospitalization. Results: In 35 aVGEI patients, the median age was 73 years (IQR 69.5–79 years), and the median Charlson Comorbidity Index score was 5 (IQR 3–6). The Management of Aortic Graft Infection Collaboration (MAGIC) criteria were fulfilled in 27 cases (77%, ‘MAGIC positive aVGEI’). The remaining eight cases (23%) were based on conference consensus, often supported by positive PET-CT findings (n = 4/8). The most frequent monomicrobial infections were Staphylococcus aureus (n = 5/35, 14.3%) and coagulase-negative staphylococci (n = 4/35, 11.4%). Polymicrobial infections occurred in nine patients (25.7%). Five aVGEI patients were treated surgically (14.3%). The 90-day mortality was 8.6% (n = 3/35, 95%CI 1.8–3.1%); 4.2% among ‘MAGIC positive aVGEI’ patients (n = 1/24), 12.5% among those diagnosed on conference consensus (n = 1/8), and 33.3% among patients with an aortoenteric fistula (AEF) (n = 1/3). Among aVGEI patients with complete follow-up, cure was achieved in 31.8% (n = 7/22, 95%CI 13.9–4.9%), but none of the three patients with AEF. Conclusion: We report low short-term mortality and a cure rate of over 30% within a cohort of predominantly conservatively managed patients discussed at an MDT conference. These outcomes may reflect the benefits of individualized treatment decisions based on careful patient evaluation during MDT meetings as well as survivor bias.
AB - Purpose: To describe the multidisciplinary management and outcomes of patients with vascular graft and endograft infections of the abdominal aorta (aVGEI) in Eastern Denmark. Methods: Retrospective cohort study of aVGEI patients between 1st July 2022 and 30th June 2025. Diagnosis and management were based on a multidisciplinary team (MDT) conference. The primary outcome was 90-day mortality. Secondary outcomes included one-year mortality, cure, remission, treatment failure, and re-hospitalization. Results: In 35 aVGEI patients, the median age was 73 years (IQR 69.5–79 years), and the median Charlson Comorbidity Index score was 5 (IQR 3–6). The Management of Aortic Graft Infection Collaboration (MAGIC) criteria were fulfilled in 27 cases (77%, ‘MAGIC positive aVGEI’). The remaining eight cases (23%) were based on conference consensus, often supported by positive PET-CT findings (n = 4/8). The most frequent monomicrobial infections were Staphylococcus aureus (n = 5/35, 14.3%) and coagulase-negative staphylococci (n = 4/35, 11.4%). Polymicrobial infections occurred in nine patients (25.7%). Five aVGEI patients were treated surgically (14.3%). The 90-day mortality was 8.6% (n = 3/35, 95%CI 1.8–3.1%); 4.2% among ‘MAGIC positive aVGEI’ patients (n = 1/24), 12.5% among those diagnosed on conference consensus (n = 1/8), and 33.3% among patients with an aortoenteric fistula (AEF) (n = 1/3). Among aVGEI patients with complete follow-up, cure was achieved in 31.8% (n = 7/22, 95%CI 13.9–4.9%), but none of the three patients with AEF. Conclusion: We report low short-term mortality and a cure rate of over 30% within a cohort of predominantly conservatively managed patients discussed at an MDT conference. These outcomes may reflect the benefits of individualized treatment decisions based on careful patient evaluation during MDT meetings as well as survivor bias.
KW - Antimicrobial therapy
KW - Aortic vascular graft and endograft infection
KW - Biofilm infections
KW - Implant-associated infections
KW - Microbiology
UR - https://www.scopus.com/pages/publications/105045033772
U2 - 10.1007/s15010-026-02885-w
DO - 10.1007/s15010-026-02885-w
M3 - Journal article
C2 - 42455267
AN - SCOPUS:105045033772
SN - 0300-8126
JO - Infection
JF - Infection
ER -